In addition to thrombosis, targets related to viral infection and viral reactivation were investigated. Therapies targeting the JAK family of enzymes may interfere with normal antiviral response including inhibition of IFN-γ activity and may potentially increase the risk of infection/ reactivation of several viral infectious diseases, particularly HZ, in RA patients. The computational approaches identified several targets expected to play a role in viral endocytosis and viral response, including epidermal growth factor receptor (EGFR) kinase and PKN2. Although, baricitinib and tofacitinib were not found to interact with EGFR in the assays used, PKN2 inhibitory activity was identified for baricitinib and tofacitinib.